Home

The Leukemia Research Group (LRG)

Main content

Anette Lodvir Hemsing(lege, stipendiat), Marte Karen Brattås(lege, stipendiat), Kristin Paulsen Rye(overingeniør), Knut Anders Mosevoll(lege, samarbeidspartner), Håkon Reikvam(gruppeleder, professor, lege) og Kimberley Hatfield(forsker, samarbeidspartner)

The Leukaemia Research Group is headed by Professor MD Håkon Reikvam.

The research has a major focus on the hematological malignancy acute myeloid leukaemia (AML); an aggressive disease that can be cured only by intensive chemotherapy eventually in combination with stem cell transplantation. Our main research areas are:

  • Biological and functional characterization of primary human AML cells and their interactions with stromal elements
  • Experimental studies of efficiency and toxicity (especially immunotoxicity) of both new targeted therapies and already established therapeutic strategies in human AML.

Collaborators

Key collaborators at the University of Bergen:

Researcher Kjell Petersen, CBU Service Group

Professor Frode Berven, Institute of Biomedicine

Professor Bjørn Tore Gjertsen, Institute of Clinical Science

Professor Lars Herfindal, Institute of Clinical Science

Professor Karl Johan Trondstad, Institute of Biomedicine

 

Key collaborators at Haukeland University Hospital:

Associate Professor Randi Hovland, Department of Medical Genetics, Haukeland University Hospital

 

External collaborators:

Dr.Tor Henrik Tvedt, The national Hospital, University of Oslo

Professor Jean-Emmanuel Sarry, Universite Toulouse III-Paul Sabatier, France

Professor Jerome Tamburini, University of Geneva, Switzerland.

Professor Kristian Koenecke, University of Hannover, Germany.

 

Funding:

University of Bergen

Norwegian Cancer Society

Helse Vest

Haukeland University Hospital

Norsk indremedisinsk forening

Caroline Musæus Aarsvolds fond

Rakel og Otto Kr. Bruuns legat

Øyvinn Mølbach-Petersen fond